If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-13. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
The enthalpy of sublimation, measured through testing of fermium alloys, is calculated at 33.8±3 kcal/mol (141.4±12.6 kJ/mol) derived from Second Law values, and 34.8 kcal/mol (145.6 kJ/mol) derived from Third Law values, both at 298 K. Through this, fermium is considered a divalent metal.
13 July Air pollution particles are shown to reduce insects' ability to find food and a mate, in experiments. This may be contributing to the dramatic fall in global insect populations, the scientists conclude. Scientists use CRISPR gene-editing to reduce the lignin content in poplar trees by as much as 50%, offering a potentially more sustainable method of fiber production. 14 July – The Indian Space Research Organisation (ISRO) successfully launches its Chandrayaan-3 spacecraft towards the Moon, aiming to become the fourth nation to achieve a soft landing on the lunar surface. 17 July – Astronomers of the Breakthrough Listen project report the development of a novel technique that can help distinguish between potential deliberate artificial alien signals and Earth-based radio interference via unique signatures from passing through ionized plasma of interstellar medium. 19 July – Astronomers report the discovery of a bizarre 'two-faced' star, with one side made up of hydrogen and the other consisting of helium. The object, designated ZTF J203349.8+322901.1, is a white dwarf located about 1,000 light years away. 18 July – The first example of naturally occurring graphene is reported, at a gold mine in South Africa. 19 July – Researchers report the discovery of self-healing of fatigue cracks in metals in vacuum.
==== Modulation of NMDA receptor ==== The effects of quisqualic acid depend on the location and context. These 2 receptors are known to potentiate the activity of N-methyl-D-aspartate receptors (NMDARs), a certain type of ion channel that is a neurotoxic. Excessive amounts of NMDA have been found to cause harm to the neurons in the presence of mGlu1 and mGlu5 receptors.
===== North America ===== The U.S. National Academy of Medicine (NAM), on behalf of both the U.S. and Canada, sets Dietary Reference Intakes, including Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs), or Adequate Intakes (AIs) for when there is not sufficient information to set EARs and RDAs. For both males and females under 9 years of age, the AIs for potassium are: 400 mg of potassium for 0 to 6-month-old infants, 860 mg of potassium for 7 to 12-month-old infants, 2,000 mg of potassium for 1 to 3-year-old children, and 2,300 mg of potassium for 4 to 8-year-old children. For males 9 years of age and older, the AIs for potassium are: 2,500 mg of potassium for 9 to 13-year-old males, 3,000 mg of potassium for 14 to 18-year-old males, and 3,400 mg for males that are 19 years of age and older. For females 9 years of age and older, the AIs for potassium are: 2,300 mg of potassium for 9 to 18-year-old females, and 2,600 mg of potassium for females that are 19 years of age and older. For pregnant and lactating females, the AIs for potassium are: 2,600 mg of potassium for 14 to 18-year-old pregnant females, 2,900 mg for pregnant females that are 19 years of age and older; furthermore, 2,500 mg of potassium for 14 to 18-year-old lactating females, and 2,800 mg for lactating females that are 19 years of age and older. As for safety, the NAM also sets tolerable upper intake levels (ULs) for vitamins and minerals, but for potassium the evidence was insufficient, so no UL was established. As of 2004, most Americans adults consume less than 3,000 mg.
Sources: en.wikipedia.org
A balanced salt solution (BSS) is a solution made to a physiological pH and isotonic salt concentration. Solutions most commonly include sodium, potassium, calcium, magnesium, and chloride. Balanced salt solutions are used for washing tissues and cells and are usually combined with other agents to treat the tissues and cells. They provide the cells with water and inorganic ions, while maintaining a physiological pH and osmotic pressure. Sometimes glucose is added as an energy source and phenol red is used as a pH indicator. In medicine, balanced salt solutions can be used as an irrigation solution such as during intraocular surgery and to replace intraocular fluids.
A biological half-life or elimination half-life is the time it takes for a substance (drug, radioactive nuclide, or other) to lose one-half of its pharmacologic, physiologic, or radiological activity. In a medical context, the half-life may also describe the time that it takes for the concentration of a substance in blood plasma to reach one-half of its steady-state value (the "plasma half-life"). The relationship between the biological and plasma half-lives of a substance can be complex, due to factors including accumulation in tissues, active metabolites, and receptor interactions. While a radioactive isotope decays almost perfectly according to first order kinetics, where the rate constant is a fixed number, the elimination of a substance from a living organism usually follows more complex chemical kinetics. For example, the biological half-life of water in a human being is about 9 to 10 days, though this can be altered by behavior and other conditions. The biological half-life of caesium in human beings is between one and four months. The concept of a half-life has also been utilized for pesticides in plants, and certain authors maintain that pesticide risk and impact assessment models rely on and are sensitive to information describing dissipation from plants. In epidemiology, the concept of half-life can refer to the length of time for the number of incident cases in a disease outbreak to drop by half, particularly if the dynamics of the outbreak can be modeled exponentially.
The amylin receptors (AMYRs) are a family of 3 receptors that are activated by amylin, a peptide hormone secreted together with insulin. They are each composed of a copy of the calcitonin receptor (CTR) bound to a receptor activity-modifying protein (RAMP), forming a heterodimer. They consist of AMY1 (RAMP1 with CTR), AMY2 (RAMP2 with CTR), and AMY3 (RAMP3 with CTR). Activation of these receptors appears to have a number of effects on eating behavior, including triggering feelings of satiation, reducing food intake, decreasing fat storage, and increasing energy usage. These effects have led to research into targeting these receptors with treatments for metabolic diseases and obesity. The amylin receptors are G protein-coupled receptor of the secretin receptor family. Consistent with their calcitonin receptor subunit, they appear to activate Gs alpha subunit pathways, and there have also been reports of Gq alpha subunit coupling. However, methodological difficulties related to amylin’s ability to bind with the calcitonin receptor have led some researchers to express uncertainty about these results.
The President believed that a pro-American China would be useful for the United States should the Americans, Soviets, and Chinese agree to jointly occupy Japan and Korea after the war. When Molotov voiced concerns about the stability of China, Roosevelt responded by saying that the combined "population of our nations and friends was well over a billion people". Roosevelt also believed China was the only Asian nation strong enough to be one of the Policemen (as Japan could not be included due to being an Axis member) and this was necessary to help avoid dividing his vision of a new global order along racial lines (Roosevelt also viewed the inclusion of what he saw as the "part-Asian" Soviets as important for the same reason). Churchill objected to Roosevelt's inclusion of China as one of the Big Four because he feared that the Americans were trying to undermine Britain's colonial holdings in Asia. In October 1942, Churchill told Eden that Republican China represented a "faggot vote on the side of the United States in any attempt to liquidate the British overseas empire." Eden shared this view with Churchill and expressed skepticism that China, which was then in the midst of a civil war, could ever return to a stable nation. Roosevelt responded to Churchill's criticism by telling Eden that "China might become a very useful power in the Far East to help police Japan" and that he was fully supportive of offering more aid to China.
A common parasite of bowfin is the anchor worm (Lernaea species). These small crustaceans infest the skin and bases of fins, with consequences ranging from slowed growth to death. The mollusk Megalonaias gigantea lays eggs in the bowfin gills that are then externally fertilized by sperm passing in the water flow. The small glochidia larvae then hatch and develop in the gill tubes. Bowfin with liver cancer or fatal leukemia have been reported.
Sources: en.wikipedia.org
=== Innovations === The initial stages of the Industrial Revolution had much to do with larger military forces—it became easy to mass-produce weapons and thus to equip larger forces. Britain was the largest single manufacturer of armaments in this period. It supplied most of the weapons used by the coalition powers throughout the conflicts. France produced the second-largest total of armaments, equipping its own huge forces as well as those of the Confederation of the Rhine and other allies. Napoleon showed innovative tendencies in his use of mobility to offset numerical disadvantages, as demonstrated in the rout of the Austro–Russian forces in 1805 in the Battle of Austerlitz. The French Army redefined the role of artillery, forming independent, mobile units, as opposed to the previous tradition of attaching artillery pieces in support of troops. The semaphore system had allowed the French War-Minister, Carnot, to communicate with French forces on the frontiers throughout the 1790s. The French continued to use this system throughout the Napoleonic wars. Aerial surveillance was used for the first time when the French used a hot-air balloon to survey coalition positions before the Battle of Fleurus, on 26 June 1794.
2 GSH + R-S-S-R → GSSG + 2 RSH The GSH:GSSG ratio is therefore an important bioindicator of cellular health, with a higher ratio signifying less oxidative stress in the organism. A lower ratio may even be indicative of neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease.
== Medical uses == In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
=== Sensory and nervous systems === Although starfish do not have many well-defined sense organs, they do perceive touch, light, temperature, orientation and the status of the water around them. The tube feet, spines and pedicellariae are sensitive to touch. The tube feet, especially those at the tips of the rays, are also sensitive to chemicals, enabling the starfish to detect odour sources such as food. There are eyespots at the ends of the arms, each one made of 80–200 simple ocelli composed of pigmented epithelial cells. Individual photoreceptor cells are present in other parts of their bodies and respond to light. Whether they advance or retreat depends on the species. Traditionally, starfish were thought to lack a centralized brain. Instead, there is a complex nervous system with a nerve ring around the mouth and a radial nerve running along the ambulacral region of each arm parallel to the radial canal. The peripheral nerve system consists of two nerve nets: one in the epidermis and the other in the lining of the coelomic cavity, which are the sensory and motor systems respectively. Neurons passing through the dermis join the two. Both the ring and radial nerves function in movement and sensory. The sensory component is supplied with information from the sensory organs while the motor nerves control the tube feet and musculature. If one arm detects something attractive, it becomes dominant and temporarily over-rides the other arms to initiate movement towards it. Recent genetic evidence, however, suggests that the majority of an echinoderm's body is "all-brain".
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.